



(51) International Patent Classification:

A61K 47/64 (2017.01) A61P 1/16 (2006.01)
A61K 48/00 (2006.01) C07K 7/64 (2006.01)
C07K 7/02 (2006.01) C12N 15/113 (2010.01)
A61K 47/54 (2017.01)

(21) International Application Number:

PCT/US2024/042608

(22) International Filing Date:

16 August 2024 (16.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/520,271	17 August 2023 (17.08.2023)	US
63/520,274	17 August 2023 (17.08.2023)	US
63/557,137	23 February 2024 (23.02.2024)	US
63/561,529	05 March 2024 (05.03.2024)	US
63/561,552	05 March 2024 (05.03.2024)	US
63/640,478	30 April 2024 (30.04.2024)	US
63/665,630	28 June 2024 (28.06.2024)	US

(71) Applicant: **ENTRADA THERAPEUTICS, INC.**
[US/US]; One Design Center Place, Suite 17-500, Boston,
Massachusetts 02210 (US).

(72) Inventors: **DOUGHERTY, Patrick**; One Design Center
Place, Suite 17-500, Boston, Massachusetts 02210 (US).
QIAN, Ziqing; One Design Center Place, Suite 17-500,
Boston, Massachusetts 02210 (US). **KHEIRABADI, Mah-
boubeh**; One Design Center Place, Suite 17-500, Boston,
Massachusetts 02210 (US). **STREETER, Matthew**; One
Design Center Place, Suite 17-500, Boston, Massachusetts
02210 (US).

(74) Agent: **PERDOK, Monique M.** et al.; P.O. Box 2938, Min-
neapolis, Minnesota 55402 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES





FIG. 1A

Linker for EEV1-PMO23-A
installed using amide conjugation

PMO-23: GGCCAAAACCTGGGTTACCTGAAT

FIG. 1C




FIG. 1B


Linker for EEV1-PMO23-B
installed using strain-promoted
alkyno azide cycloaddition (SPAAC)EEV1: Ac-FKKKRVK-PEG₄-K(cyano[F(NH₂)C(=O)-C(=O)-L-Ala]-PNC

FIG. 1D

(57) Abstract: Compounds are provided include a cyclic cell penetrating peptide (cCPP) and one or more linkers comprising, an amino acid component, a polyethylene glycol component, a hydrophobic component, or a combination thereof. In embodiments, the compound includes an exocyclic peptide (EP). In embodiments, the compound does not include an exocyclic peptide.

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
20 March 2025 (20.03.2025)